Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.

AIM To determine the overall survival rate, radical resection rate, objective response rate and safety of capecitabine plus paclitaxel induction chemotherapy in gastric cancer patients with liver metastases. PATIENTS & METHODS A total of 30 patients (median age: 59.5 years) diagnosed as gastric adenocarcinoma with liver metastasis received ≥3 cycles of capecitabine and paclitaxel therapy followed by radical resection 4-6 weeks after termination of chemotherapy. RESULTS The median survival time was 11.4 months, and the objective response rate was 53.3%. The radical resection rate was 23.3% (95% CI: 9.9-42.3). Major toxicities included grade 3 neutropenia (10.0%) and grade 3 diarrhea (3.3%). CONCLUSION Capecitabine plus paclitaxel chemotherapy may be effective and safe to improve overall survival and the resection rate of gastric cancer patients with liver metastases. ClinicalTrials.gov identifier: NCT0116704.

[1]  S. Hahn,et al.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. , 2016, The Lancet. Oncology.

[2]  B. Xiong,et al.  An Updated Meta-Analysis of Randomized Controlled Trial Assessing the Effect of Neoadjuvant Chemotherapy in Advanced Gastric Cancer , 2014, Cancer investigation.

[3]  Ying Cheng,et al.  The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. , 2014, The oncologist.

[4]  D. Reim,et al.  Neoadjuvant Treatment for Gastric Cancer , 2013, Journal of gastric cancer.

[5]  F. Giuliante,et al.  Liver resection for gastric cancer metastases. , 2013, Hepato-gastroenterology.

[6]  Jianping Wang,et al.  Neoadjuvant chemotherapy for gastric cancer: A meta‐analysis of randomized, controlled trials , 2013, Journal of gastroenterology and hepatology.

[7]  L. Gianotti,et al.  Surgical treatment of liver metastases of gastric cancer: state of the art , 2012, World Journal of Surgical Oncology.

[8]  A. Sonnenberg,et al.  Epidemiology of Noncardia Gastric Adenocarcinoma in the United States , 2011, The American Journal of Gastroenterology.

[9]  Lin Chen,et al.  Current status and progress in gastric cancer with liver metastasis. , 2011, Chinese medical journal.

[10]  Yihong Sun,et al.  Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. , 2010, World journal of gastroenterology.

[11]  J. Yook,et al.  A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer , 2008, British Journal of Cancer.

[12]  Y. Seto,et al.  Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. , 2007, Japanese journal of clinical oncology.

[13]  K. Abbrederis,et al.  Gibt es eine Indikation zur Lebermetastasenresektion bei Patientinnen mit hepatisch metastasiertem Mammakarzinom? , 2007, Der Chirurg.

[14]  H. Kuwano,et al.  Treatment of multiple liver metastasis from gastric carcinoma , 2007, World journal of surgical oncology.

[15]  H. Katai,et al.  Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer , 2007, Journal of surgical oncology.

[16]  K. Shirabe,et al.  Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. , 2006, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[17]  K. Takeda,et al.  Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. , 2005, Journal of vascular and interventional radiology : JVIR.

[18]  J. Ajani.  Evolving chemotherapy for advanced gastric cancer. , 2005, The oncologist.

[19]  Alan Y Chiang,et al.  Book Review: Statistical methods for rates and proportions, 3rd edition , 2005 .

[20]  H. Putter,et al.  Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  M. Makuuchi,et al.  Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. , 2003, Surgery.

[22]  J. Takamizawa,et al.  Resection of liver metastasis from gastric adenocarcinoma. , 2001, Hepato-gastroenterology.

[23]  R. Newcombe.  Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.

[24]  M. Miyazaki,et al.  Hepatic resection of liver metastases from gastric carcinoma. , 1997, The American journal of gastroenterology.

[25]  C. Earle,et al.  Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America , 2012, Gastric Cancer.

[26]  C. Mariette,et al.  Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy? , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[27]  L. Wyrwicz,et al.  Capecitabine in the treatment of advanced gastric cancer , 2011 .

[28]  김혜련.  Efficacy and Feasibility of Radiofrequency Ablation for Liver Metastases from Gastric Adenocarcinoma , 2010 .